NASDAQ:PRTK Paratek Pharmaceuticals (PRTK) Stock Price, News & Analysis → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Free PRTK Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.19▼$2.2450-Day Range$2.17▼$2.2352-Week Range$1.29▼$3.65Volume4.76 million shsAverage Volume724,253 shsMarket Capitalization$127.82 millionP/E RatioN/ADividend YieldN/APrice Target$3.58 Stock AnalysisStock Analysis Get Paratek Pharmaceuticals alerts: Email Address Paratek Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside60.3% Upside$3.58 Price TargetShort InterestN/ADividend StrengthN/ASustainability-2.98Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.53 out of 5 starsMedical Sector870th out of 918 stocksBiotechnology Industry38th out of 43 stocks 3.0 Analyst's Opinion Consensus RatingParatek Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageParatek Pharmaceuticals has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for PRTK. Previous Next 0.0 Dividend Strength Dividend YieldParatek Pharmaceuticals does not currently pay a dividend.Dividend GrowthParatek Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreParatek Pharmaceuticals has received a -34.94% net impact score from Upright. The largest negative impact of Paratek Pharmaceuticals in category "Physical diseases" is driven by its "Tetracyclines" product. See details.Environmental SustainabilityThe Environmental Impact score for Paratek Pharmaceuticals is -2.98. Previous Next N/A News and Social Media Coverage Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Paratek Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.00% of the stock of Paratek Pharmaceuticals is held by insiders.Percentage Held by Institutions53.60% of the stock of Paratek Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Paratek Pharmaceuticals is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Paratek Pharmaceuticals is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIBiden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full story About Paratek Pharmaceuticals Stock (NASDAQ:PRTK)Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.Read More Ad DTIBiden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full story PRTK Stock News HeadlinesMarch 5, 2024 | markets.businessinsider.comParatek Reports Positive Data For Nuzyra As Post-exposure Prophylaxis Of Pulmonary Anthrax In NHPsFebruary 24, 2024 | benzinga.comMira Pharmaceuticals Stock (NASDAQ:MIRA) Dividends: History, Yield and DatesApril 19, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.October 5, 2023 | finance.yahoo.comParatek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023September 21, 2023 | finance.yahoo.comNovo Holdings closes $462 mln acquisition of Paratek PharmaceuticalsSeptember 21, 2023 | finance.yahoo.comGurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.September 19, 2023 | finance.yahoo.comParatek Pharmaceuticals, Inc. (NASDAQ:PRTK) is definitely on the radar of institutional investors who own 48% of the companySeptember 18, 2023 | bizjournals.comParatek Pharmaceuticals shareholders approve $462M buyout dealApril 19, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.September 18, 2023 | finance.yahoo.comParatek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/SSeptember 12, 2023 | finance.yahoo.comSecond Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/SSeptember 7, 2023 | finance.yahoo.comLeading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo HoldingsAugust 10, 2023 | benzinga.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TRTN, AMED, PRTKAugust 7, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Hold Rating on Paratek Pharmaceuticals (PRTK)August 4, 2023 | finance.yahoo.comNews Flash: Analysts Just Made A Captivating Upgrade To Their Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) ForecastsAugust 3, 2023 | finance.yahoo.comParatek Pharmaceuticals Files Definitive Proxy Statement and Letter to Stockholders in Connection with Acquisition by Gurnet Point Capital and Novo HoldingsAugust 3, 2023 | finance.yahoo.comParatek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0 MillionJuly 27, 2023 | seekingalpha.comPRTK Paratek Pharmaceuticals, Inc.July 11, 2023 | finance.yahoo.comNexPoint Sends Demand Letter for Books and Records to Paratek Pharmaceuticals in Connection with Proposed Acquisition by Gurnet Point CapitalJuly 11, 2023 | msn.comHC Wainwright & Co. Reiterates Paratek Pharmaceuticals (PRTK) Neutral RecommendationJuly 10, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Hold Rating on Paratek Pharmaceuticals (PRTK)July 10, 2023 | finance.yahoo.comParatek Pharmaceuticals Announces Modification of BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary AnthraxJuly 6, 2023 | msn.comParatek Pharmaceuticals (PRTK) Price Target Decreased by 41.87% to 3.16June 27, 2023 | msn.comParatek antibiotic Nuzyra to receive EU orphan drug statusJune 27, 2023 | msn.comParatek investor NexPoint warns it may vote against takeover dealJune 27, 2023 | finance.yahoo.comParatek Pharmaceuticals Acknowledges Receipt of NexPoint LetterJune 27, 2023 | finance.yahoo.comNexPoint Asset Management Sends Open Letter to the Board of Paratek Pharmaceuticals Regarding Upcoming Annual Meeting and Proposed Acquisition by Gurnet Point CapitalSee More Headlines Receive PRTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Paratek Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2021Today4/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PRTK Previous SymbolNASDAQ:TSPT CUSIP89354M10 CIK1178711 Webwww.paratekpharma.com Phone(617) 807-6600Fax617-275-0039Employees268Year Founded1996Price Target and Rating Average Stock Price Target$3.58 High Stock Price Target$5.00 Low Stock Price Target$2.15 Potential Upside/Downside+60.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,570,000.00 Net Margins-35.44% Pretax Margin-35.35% Return on EquityN/A Return on Assets-40.05% Debt Debt-to-Equity RatioN/A Current Ratio0.52 Quick Ratio0.46 Sales & Book Value Annual Sales$160.27 million Price / Sales0.80 Cash FlowN/A Price / Cash FlowN/A Book Value($3.08) per share Price / Book-0.72Miscellaneous Outstanding Shares57,320,000Free Float52,736,000Market Cap$127.82 million OptionableOptionable Beta1.70 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Michael F. Bigham CPA (Age 65)CPA, M.B.A., MBA, Exec. Chairman Comp: $954.39kDr. Evan Loh FACC (Age 64)FAHA, M.D., CEO & Director Comp: $1.14MMr. Adam Woodrow (Age 56)Pres & Chief Commercial Officer Comp: $763.51kMs. Sarah Higgins (Age 48)VP of Fin., Controller & Principal Accounting Officer Mr. William M. Haskel (Age 61)Sr. VP, Chief Legal Officer, Gen. Counsel & Corp. Sec. Mr. Jonathan LightDeputy Gen. Counsel & Chief Compliance OfficerMs. Karen McGrathChief People OfficerMr. Randall B. Brenner (Age 50)Chief Devel. & Regulatory Officer More ExecutivesKey CompetitorsAssembly BiosciencesNASDAQ:ASMBNGM BiopharmaceuticalsNASDAQ:NGMKinnate BiopharmaNASDAQ:KNTEProQR TherapeuticsNASDAQ:PRQRHookipa PharmaNASDAQ:HOOKView All CompetitorsInsidersMichael BighamSold 31,250 sharesTotal: $68,750.00 ($2.20/share)Evan LohSold 48,967 sharesTotal: $107,727.40 ($2.20/share)William M HaskelSold 34,526 sharesTotal: $75,957.20 ($2.20/share)Randall B BrennerSold 27,603 sharesTotal: $60,726.60 ($2.20/share) PRTK Stock Analysis - Frequently Asked Questions Should I buy or sell Paratek Pharmaceuticals stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" PRTK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRTK, but not buy additional shares or sell existing shares. View PRTK analyst ratings or view top-rated stocks. What is Paratek Pharmaceuticals' stock price target for 2024? 2 analysts have issued 1-year price targets for Paratek Pharmaceuticals' shares. Their PRTK share price targets range from $2.15 to $5.00. On average, they anticipate the company's share price to reach $3.58 in the next twelve months. This suggests a possible upside of 60.3% from the stock's current price. View analysts price targets for PRTK or view top-rated stocks among Wall Street analysts. How were Paratek Pharmaceuticals' earnings last quarter? Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) posted its earnings results on Monday, November, 8th. The specialty pharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.08. The specialty pharmaceutical company earned $24.45 million during the quarter, compared to analysts' expectations of $22.98 million. During the same period last year, the firm posted ($0.46) earnings per share. What other stocks do shareholders of Paratek Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Paratek Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), CBL & Associates Properties (CBL), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Aduro Biotech (ADRO), Corbus Pharmaceuticals (CRBP) and Rigel Pharmaceuticals (RIGL). This page (NASDAQ:PRTK) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingBiden’s $374B Giveaway Into This SectorDTIThe “Perfect Storm” for GoldGold Safe ExchangeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for 2024InvestorPlaceUrgent alert: open this for a huge profit potentialTimothy SykesHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Paratek Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.